Conference: Gene Therapy for Rare Disorders (GTRD), 2024

2024-03-13T14:58:51-04:00Cell & Gene Therapy, Events, Thought Leadership|

Precision will be at this year’s Gene Therapy for Rare Disorders on March 26-29, 2024, in Boston, MA. Connect with our team of experts as they lead meaningful presentations and discussions throughout this event providing insights into the clinical development, manufacturing, and commercialization for gene therapies.

Speaking Engagements
Detailed descriptions for each speaking engagement are included below. 

  • Precision will have a plenary speaking position on March 27, 2024, 8:30 – 9:00 am.
  • Precision’s Andy Kinley (VP, Innovation & Clinical Science, Precision for Medicine) will Chair the Clinical track session, “Clinical Endpoints for Rare Disease Studies,” on March 28, 2024, 11:15 am – 12:15 pm.

Connect with our Advanced Therapy experts

  • Schedule in-person or virtual meetings with our team

Plenary Speaking Position: What to Look Forward to for Gene Therapy in 2024
Precision | March 27, 2024, 8:30 – 9AM ET 

  • Key Takeaways
    • Market trends and expectations for Gene Therapies & Rare Diseases in 2024 
    • Predictions on Potential Approvals in 2024 
    • Innovative Trends & Technologies 
    • Evolution of CMC and manufacturing 


  • [Moderator] Jake Greenwood, VP, Project Farma  
  • Faraz Ali, CEO, Tenaya Therapeutics  
  • Debs Phippard, CSO, Precision for Medicine  
  • Frank Bugg, Global Head of BaseCamp Operations & Commercial, ElevateBio  

Panel Discussion: Manufacturing Track: Capacity versus Capability – Moving Towards Innovative Manufacturing Processes
Precision | March 28, 2024, 11:15AM – 12:15PM ET

  • Andy Kinley, VP, Innovation & Clinical Science (Precision for Medicine) to Chair

Simon Fleming Joins Precision

2024-02-13T07:37:58-05:00Cell & Gene Therapy, News|

Simon Fleming has joined the Precision leadership team as Executive Vice President, Clinical Solutions. With over 30 years of experience leading global functions at a large CRO, Simon’s invaluable expertise will strengthen Precision across multiple fronts. He brings an impressive track record of performance, technical skills, and passion for aligning teams to drive research forward. We are confident Simon will make immediate strategic contributions as we continue advancing and accelerating the development of life-changing innovations.




Precision Medicine Group Releases Its Inaugural Environmental, Social and Governance (ESG) Report

2023-12-14T08:40:44-05:00Cell & Gene Therapy, News, Thought Leadership|

Precision is proud to have published our inaugural 2023 Environmental, Social and Governance (ESG) Report, reflecting the company’s ongoing efforts to do better for our people, in our practices, and with the broader community at large. This year’s report shares key achievements, performance metrics, and steps we have taken to enhance sustainability throughout the company, including:

· Engaging internal and external stakeholders in our company’s first ESG materiality assessment to identify and prioritize our material issues

· Defining Precision’s approach to ESG in our company’s ESG Strategy Statement · Creating a three-year strategic ESG Roadmap for advancing our performance across environmental, social, and governance issues · Initiating energy efficiency projects and standards across our facilities

· Implementing implicit bias training for our Executive Leadership Team and Human Resources leaders

· Contributing volunteer hours by over 425 employees and over $250,000 in donations to more than 70 charitable foundations and causes



White Paper: Unleashing the Power of Precision Medicine: Radioligand Therapy

2023-11-03T16:36:34-04:00Cell & Gene Therapy, News, Thought Leadership|

This article was originally published on This Month in Transformative Medicine on October 17, 2023

The current standard of cancer care has saved many lives, but these methods often come with incredibly difficult side effects. Advancements in technology have brought new options to cancer care that hope to provide meaningful outcomes while minimizing the impact to the patient’s quality of life.

In this white paper Anshul Mangal, President of Project Farma (PF) & Precision ADVANCE, and Sumit Verma, Co-founder and Partner at Orchestra Life Sciences, discuss the power and potential of radioligand therapies and its impact on the treatment of a number of cancers.


On Demand: State of the Union for Advanced Therapies

2023-11-14T10:42:38-05:00Cell & Gene Therapy, Events|

Sponsored by Precision ADVANCE, this Endpoints webinar convened industry leaders to discuss the current state of the industry, and the future of advanced therapies including innovations in research and development, going from treating rare diseases to prevalent conditions, continued investment, and next-generation technologies. The panelists also discussed manufacturing and talent bottlenecks, and innovative reimbursement payment models. This discussion was moderated by Anshul Mangal: President (Precision ADVANCE & Project Farma), and included insights from Dan Kirby: Chief Commercial Officer (Orca Bio), Deborah Phippard: CSO (Precision for Medicine), Devyn Smith: CEO (Arbor Bio), Helen Sabzevari: President & CEO (Precigen) and Chad Salisbury: SVP (Project Farma). 


White Paper: Scaling Hope: The Growth of the Allogeneic Cell Therapy Sector

2023-09-22T15:39:39-04:00Cell & Gene Therapy, News, Thought Leadership|

In the rapidly evolving landscape of advanced therapies, allogeneic cell therapies have emerged as a promising avenue for addressing various disorders, including hematological malignancies, neurological conditions, and autoimmune or inflammatory diseases. With a number of clinical trials underway to evaluate their efficacy, allogeneic cell therapies hold significant potential in reshaping the way we approach treating numerous diseases.

In this white paper, Anshul Mangal, President of Project Farma & Precision ADVANCE and John Khoury, Executive Vice President of Project Farma (PF), discuss the growth of the allogeneic cell therapy sector and its impact on patient access.


Webinar: Rise of mRNA manufacturing

2023-09-13T19:38:47-04:00Cell & Gene Therapy, Events|

Sponsored by Project Farma, a Precision for Medicine Company, this panel will feature insights from industry leaders on the current state of the market for mRNA-based medicines, techniques to optimize manufacturing and technical operations, and strategies for CQV, quality, automation & engineering for mRNA facilities.

This discussion will be moderated by Anshul Mangal: President (Project Farma & Precision ADVANCE), and include insights from Aaron Allen: Director, Global Quality, External Engagement (Moderna), Andrew Geall: Co-founder and Chief Development Officer (Replicate Bioscience), Jane True: Global VP, mRNA Commercial Strategy Innovation & Pandemic Security Lead (Pfizer), Venkata Indurthi: CSO (Aldevron), and Chad Salisbury: SVP (Project Farma).


White Paper: Cell and Gene Therapies: How High Can Prices Go?

2023-08-11T13:10:02-04:00Cell & Gene Therapy, News, Thought Leadership|

The concept of optimizing CGT value propositions begs the question of what is reasonable when it comes to breakthrough science and unprecedented therapeutic solutions. Can a $5 million price tag be justified? What about $10 million?

This white paper is based on a webinar convened by PRECISIONadvisors, focusing on cell and gene therapy (CGT) pricing. The webinar featured two in-house experts from the PRECISIONadvisors Global Pricing & Market Access practice: Richard Macaulay, Senior Vice President and David Carr, Senior Director.


On Demand: The Future of Cell Therapy Development and Delivery

2023-08-24T13:19:48-04:00Cell & Gene Therapy, Events|

Sponsored by Precision ADVANCE, this Endpoints webinar convened leading advanced therapy experts to discuss the future of cell therapy development and delivery. This discussion was moderated by John Khoury: EVP (Project Farma), and included insights from Chris McDonald: Global Head of Tech Ops (Kite Pharma), Mark Frattini: CMO (Cellectis), Jason Foster: CEO & ED (Ori Biotech), and Phil Cyr: SVP (Precision Value & Health).


Load More Posts